世界の肝性脳症（HE）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Hepatic Encephalopathy (HE) Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2778
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、91ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品、ヘルスケア

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、肝性脳症（HE）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ラクツロース、リファキシミン、ネオマイシン、プロバイオティクス、チアミン）、用途別市場規模（急性肝不全、肝硬変）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・肝性脳症（HE）治療の市場動向
・企業の競争状況、市場シェア
・肝性脳症（HE）治療の種類別市場規模（ラクツロース、リファキシミン、ネオマイシン、プロバイオティクス、チアミン）
・肝性脳症（HE）治療の用途別市場規模（急性肝不全、肝硬変）
・肝性脳症（HE）治療の北米市場規模2016-2027（アメリカ、カナダ）
・肝性脳症（HE）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・肝性脳症（HE）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・肝性脳症（HE）治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・肝性脳症（HE）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（ASKA Pharmaceutical、COSMO PHARMACEUTICALS、Mallinckrodt、Valeant）
・結論

HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutics market till 2023. Such programs increase the adherence to therapeutics by improving convenience for patients. Norgine collaborated with the European liver patients association (ELPA) to launch Time to DeLiver program, which is focused on changing the perception about HE among all stakeholders, healthcare professionals, and policymakers. This in turn, drives the demand for diagnosis and management of HE.

Market Analysis and Insights: Global Hepatic Encephalopathy (HE) Therapeutics Market
The global Hepatic Encephalopathy (HE) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hepatic Encephalopathy (HE) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hepatic Encephalopathy (HE) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hepatic Encephalopathy (HE) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hepatic Encephalopathy (HE) Therapeutics market.

Global Hepatic Encephalopathy (HE) Therapeutics Scope and Market Size
Hepatic Encephalopathy (HE) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hepatic Encephalopathy (HE) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Lactulose
Rifaximin
Neomycin
Probiotics
Thiamine

Segment by Application
Acute Liver Failure
Liver Cirrhosis

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
ASKA Pharmaceutical
COSMO PHARMACEUTICALS
Mallinckrodt

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Lactulose
1.2.3 Rifaximin
1.2.4 Neomycin
1.2.5 Probiotics
1.2.6 Thiamine
1.3 Market by Application
1.3.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Acute Liver Failure
1.3.3 Liver Cirrhosis
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Perspective (2016-2027)
2.2 Hepatic Encephalopathy (HE) Therapeutics Growth Trends by Regions
2.2.1 Hepatic Encephalopathy (HE) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hepatic Encephalopathy (HE) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Hepatic Encephalopathy (HE) Therapeutics Industry Dynamic
2.3.1 Hepatic Encephalopathy (HE) Therapeutics Market Trends
2.3.2 Hepatic Encephalopathy (HE) Therapeutics Market Drivers
2.3.3 Hepatic Encephalopathy (HE) Therapeutics Market Challenges
2.3.4 Hepatic Encephalopathy (HE) Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Revenue
3.1.1 Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hepatic Encephalopathy (HE) Therapeutics Revenue
3.4 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio
3.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy (HE) Therapeutics Revenue in 2020
3.5 Hepatic Encephalopathy (HE) Therapeutics Key Players Head office and Area Served
3.6 Key Players Hepatic Encephalopathy (HE) Therapeutics Product Solution and Service
3.7 Date of Enter into Hepatic Encephalopathy (HE) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
4.1 Global Hepatic Encephalopathy (HE) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
5.1 Global Hepatic Encephalopathy (HE) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size (2016-2027)
6.2 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
6.2.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2027)
6.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
6.3.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2027)
6.4 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country
6.4.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size (2016-2027)
7.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
7.2.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
7.3.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country
7.4.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size (2016-2027)
9.2 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
9.2.1 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
9.3.1 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country
9.4.1 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 ASKA Pharmaceutical
11.1.1 ASKA Pharmaceutical Company Details
11.1.2 ASKA Pharmaceutical Business Overview
11.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Introduction
11.1.4 ASKA Pharmaceutical Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021)
11.1.5 ASKA Pharmaceutical Recent Development
11.2 COSMO PHARMACEUTICALS
11.2.1 COSMO PHARMACEUTICALS Company Details
11.2.2 COSMO PHARMACEUTICALS Business Overview
11.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Introduction
11.2.4 COSMO PHARMACEUTICALS Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021)
11.2.5 COSMO PHARMACEUTICALS Recent Development
11.3 Mallinckrodt
11.3.1 Mallinckrodt Company Details
11.3.2 Mallinckrodt Business Overview
11.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Introduction
11.3.4 Mallinckrodt Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021)
11.3.5 Mallinckrodt Recent Development
11.4 Valeant
11.4.1 Valeant Company Details
11.4.2 Valeant Business Overview
11.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Introduction
11.4.4 Valeant Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021)
11.4.5 Valeant Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Lactulose
Table 3. Key Players of Rifaximin
Table 4. Key Players of Neomycin
Table 5. Key Players of Probiotics
Table 6. Key Players of Thiamine
Table 7. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Regions (2016-2021)
Table 11. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Regions (2022-2027)
Table 13. Hepatic Encephalopathy (HE) Therapeutics Market Trends
Table 14. Hepatic Encephalopathy (HE) Therapeutics Market Drivers
Table 15. Hepatic Encephalopathy (HE) Therapeutics Market Challenges
Table 16. Hepatic Encephalopathy (HE) Therapeutics Market Restraints
Table 17. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Players (2016-2021)
Table 19. Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Encephalopathy (HE) Therapeutics as of 2020)
Table 20. Ranking of Global Top Hepatic Encephalopathy (HE) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Hepatic Encephalopathy (HE) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Hepatic Encephalopathy (HE) Therapeutics Product Solution and Service
Table 24. Date of Enter into Hepatic Encephalopathy (HE) Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. ASKA Pharmaceutical Company Details
Table 65. ASKA Pharmaceutical Business Overview
Table 66. ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Product
Table 67. ASKA Pharmaceutical Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021) & (US$ Million)
Table 68. ASKA Pharmaceutical Recent Development
Table 69. COSMO PHARMACEUTICALS Company Details
Table 70. COSMO PHARMACEUTICALS Business Overview
Table 71. COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Product
Table 72. COSMO PHARMACEUTICALS Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021) & (US$ Million)
Table 73. COSMO PHARMACEUTICALS Recent Development
Table 74. Mallinckrodt Company Details
Table 75. Mallinckrodt Business Overview
Table 76. Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Product
Table 77. Mallinckrodt Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021) & (US$ Million)
Table 78. Mallinckrodt Recent Development
Table 79. Valeant Company Details
Table 80. Valeant Business Overview
Table 81. Valeant Hepatic Encephalopathy (HE) Therapeutics Product
Table 82. Valeant Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021) & (US$ Million)
Table 83. Valeant Recent Development
Table 84. Research Programs/Design for This Report
Table 85. Key Data Information from Secondary Sources
Table 86. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Lactulose Features
Figure 3. Rifaximin Features
Figure 4. Neomycin Features
Figure 5. Probiotics Features
Figure 6. Thiamine Features
Figure 7. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Application: 2020 VS 2027
Figure 8. Acute Liver Failure Case Studies
Figure 9. Liver Cirrhosis Case Studies
Figure 10. Hepatic Encephalopathy (HE) Therapeutics Report Years Considered
Figure 11. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 14. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Regions (2022-2027)
Figure 15. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Players in 2020
Figure 16. Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Encephalopathy (HE) Therapeutics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Hepatic Encephalopathy (HE) Therapeutics Revenue in 2020
Figure 18. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 19. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 20. North America Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2016-2027)
Figure 22. North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2016-2027)
Figure 23. North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2016-2027)
Figure 24. United States Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2016-2027)
Figure 28. Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2016-2027)
Figure 29. Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2016-2027)
Figure 30. Germany Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2016-2027)
Figure 40. China Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2016-2027)
Figure 48. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2016-2027)
Figure 49. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2016-2027)
Figure 50. Mexico Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2016-2027)
Figure 56. Turkey Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. ASKA Pharmaceutical Revenue Growth Rate in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021)
Figure 60. COSMO PHARMACEUTICALS Revenue Growth Rate in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021)
Figure 61. Mallinckrodt Revenue Growth Rate in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021)
Figure 62. Valeant Revenue Growth Rate in Hepatic Encephalopathy (HE) Therapeutics Business (2016-2021)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

以下、関連資料のご紹介

世界の顕性肝性脳症市場規模・現状・予測（2021年-2027年）

Global Overt Hepatic Encephalopathy Market Size, Status and Forecast 2021-2027
QYR2104Z4387 2021年4月 93Pages
QYResearch社発行の本調査資料では、顕性肝性脳症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（タイプA（急性肝不全）、タイプB（肝疾患のない門脈全身バイパス）、タイプC（肝硬変））、用途別市場規模（病院、研究機関、診療所、その他）、主...

世界の顕性肝性脳症市場規模・現状・予測（2021年-2027年）

世界の肝性脳症治療薬市場 2021：企業別、地域別、種類・用途別

Global Hepatic Encephalopathy Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z06887 2021年4月 103Pages
当調査資料では、肝性脳症治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。肝性脳症治療薬の種類別市場規模（キット、試薬、機器）、用途別市場規模（急性肝不全、非肝疾患門脈全身バイパス、肝硬変）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国...

世界の急性間欠性ポルフィリン症（AIP）治療市場規模・現状・予測（2021年-2027年）

Global Acute Intermittent Porphyria Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z0059 2021年4月 90Pages
QYResearch社発行の本調査資料では、急性間欠性ポルフィリン症（AIP）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（350mg、313mg）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日...

世界のサイトメガロウイルス（CMV）治療市場規模・現状・予測（2021年-2027年）

Global Cytomegalovirus Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z1707 2021年4月 90Pages
QYResearch社発行の本調査資料では、サイトメガロウイルス（CMV）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ガンシクロビル/バルガンシクロビル、ホスカルネット、シドフォビル）、用途別市場規模（CMV網膜炎、肺炎、消化性潰瘍、脳...

世界のサイトメガロウイルス（CMV）治療市場規模・現状・予測（2021年-2027年）

世界の自閉症スペクトラム障害（ASD）診断・治療市場規模・現状・予測（2021年-2027年）

Global Autism Spectrum Disorder Diagnosis and Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z0512 2021年4月 95Pages
QYResearch社発行の本調査資料では、自閉症スペクトラム障害（ASD）診断・治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（自閉症、アスペルガー症候群、小児期崩壊性障害、その他）、用途別市場規模（子供・十代、成人）、主要地域別市場規模...

世界の胃食道逆流症（GERD）治療市場規模・現状・予測（2021年-2027年）

Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z2493 2021年4月 96Pages
QYResearch社発行の本調査資料では、胃食道逆流症（GERD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（制酸剤、運動促進薬、H2受容体遮断薬、プロトンポンプ阻害薬（PPI））、用途別市場規模（胸焼け、胃酸逆流症）、主要地域別市場...

世界の脳卒中診断＆治療市場規模・現状・予測（2021年-2027年）

Global Stroke Diagnostics and Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z5464 2021年4月 91Pages
QYResearch社発行の本調査資料では、脳卒中診断＆治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（診断、治療）、用途別市場規模（虚血性脳卒中、出血性脳卒中）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、イ...

世界の胃食道逆流症（GERD）治療市場規模・現状・予測（2021年-2027年）

Global Gastroesophageal Reflux Disease Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z2494 2021年4月 93Pages
QYResearch社発行の本調査資料では、胃食道逆流症（GERD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（制酸剤、H2受容体遮断薬、プロトンポンプ阻害薬（PPI）、運動促進薬、その他）、用途別市場規模（病院薬局、ドラッグストア、雑...

世界の肝性脳症治療薬市場 2021：企業別、地域別、種類・用途別 The Hepatic Encephalopathy Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…
世界の顕性肝性脳症市場規模・現状・予測（2021年-2027年） Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma. Overt hepatic encephalopathy develo…
世界の顕性肝性脳症市場規模・現状・予測（2021年-2027年） Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma. Overt hepatic encephalopathy develo…
世界の肝不全治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Liver Failure Therapeutics Market The global Liver Failure Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, …
世界の肝不全治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Liver Failure Therapeutics Market The global Liver Failure Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, …